Tempus expands ai-enabled care pathway intelligence platform into breast cancer

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced the expansion of its care pathway intelligence platform, tempus next, into breast cancer. since its launch in 2024, tempus next has screened thousands of patients across its network of provider sites, helping close critical care gaps for patients with lung cancer. now, the platform will support five different biomarker testing g.
TEM Ratings Summary
TEM Quant Ranking